Compound profile
Thymosin Alpha-1
Stronger clinical signalAlso known as: Zadaxin · Thymalfasin · Tα1
A 28-amino-acid immunomodulatory peptide, marketed in dozens of countries as Zadaxin/thymalfasin for chronic viral hepatitis and as an immune-response adjunct in cancer and infection. One of the few peptides in this space with genuine international drug-approval history.
Overview
Thymosin alpha 1 is a 28 amino acid peptide originally identified as one of the active components of thymosin fraction 5, a partially purified extract of calf thymus tissue that researchers in the 1960s and 1970s were studying for its ability to restore immune function in animals whose thymus had been removed. Allan Goldstein and colleagues at the University of Texas Medical Branch in Galveston isolated and characterized it as a distinct molecule in 1977, describing an N-terminal acetylated, 28 amino acid peptide with a molecular weight of about 3,108 daltons.
Unlike most peptides discussed on this site, thymosin alpha 1 has real international drug approval history under the name thymalfasin, sold commercially as Zadaxin. It is approved in more than 35 countries, largely across Asia, Latin America, and parts of Europe, primarily for chronic hepatitis B, and has also been used as an adjunct in some cancer and immune deficiency treatment contexts abroad. That places it in a different regulatory category from most research peptides covered here, closer to tirzepatide or bremelanotide in having gone through actual drug approval processes, just not in the United States.
In the US specifically, thymosin alpha 1 has never received FDA approval as a prescription drug. It is available only through licensed compounding pharmacies operating under 503A rules, which is a narrower and more provider dependent path than a fully approved medicine, and its status there has been the subject of ongoing FDA review regarding which bulk peptide substances compounders may legally use.
Mechanism (plain language)
Promotes maturation and function of T-cells and enhances antigen-presenting cell activity, supporting broader antiviral and antitumor immune responses without being a direct antimicrobial or cytotoxic agent itself.
How it works
The thymus gland trains and matures T-cells, the immune system's primary coordinators of adaptive immunity, and thymosin alpha 1 is one of the signaling peptides thought to support that maturation process. Research describes it promoting the differentiation and functional activity of T-cells and enhancing the activity of dendritic cells and other antigen presenting cells, the immune cells responsible for identifying threats like viruses and abnormal cells and presenting them to the rest of the immune system for a coordinated response.
Because of this, thymosin alpha 1 is not an antiviral or cytotoxic agent in the way that a drug directly killing a virus or tumor cell would be. It works upstream of that, supporting the body's own immune machinery so it can mount a more effective response on its own, which is the rationale behind its approved use in chronic hepatitis B, where the goal is to help the immune system clear or suppress the virus more effectively, sometimes alongside antiviral drugs like interferon rather than in place of them.
What research suggests
Randomized trials in chronic hepatitis B (alone and combined with interferon) report improved viral suppression and liver-function normalization; a further RCT in HBV-related acute-on-chronic liver failure reported improved transplant-free survival. Broader use spans cancer adjuvant therapy and immune deficiency contexts internationally.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Viral suppression in chronic hepatitis B
Randomized trials, both as monotherapy and combined with interferon, report improved viral suppression and normalization of liver function markers in chronic hepatitis B, the peptide's core approved indication abroad.
Survival in acute-on-chronic liver failure
A randomized controlled trial of 120 patients with hepatitis B related acute-on-chronic liver failure found significantly higher 90 day transplant-free survival with thymosin alpha 1 added to standard therapy.
Adjunct use in oncology and immune deficiency
It has been studied and used in some countries as an adjunct in certain cancer treatment protocols and in immune deficiency contexts, intended to support immune function rather than act as a primary anticancer therapy.
Combined use with interferon in hepatitis C
Older combination trials with interferon report additional benefit in chronic hepatitis C compared with interferon alone, though this use has become less central as direct acting antiviral drugs have transformed hepatitis C treatment.
Uncertainties & risks
Approved abroad but not FDA-approved in the US as a prescription drug; most large trials are in specific hepatology/oncology populations, not healthy individuals seeking general immune support. Response rates in some hepatitis trials were moderate (around 50%), and combination-therapy questions remain open.
Thymosin alpha 1's evidence base is genuinely stronger than most peptides discussed in research and biohacking communities, since it includes randomized controlled trials in defined patient populations with hard clinical endpoints. But that evidence is concentrated in specific hepatology and, to a lesser extent, oncology populations, not in healthy people seeking general immune support, which is how it is most often marketed and discussed online. Response rates in some of the hepatitis trials were moderate, around half of treated patients, and open questions remain about optimal combination with other antiviral drugs and about which patient subgroups benefit most. It is not FDA approved in the United States, so anyone accessing it there is doing so through a 503A compounding pharmacy under a prescriber's direction rather than through a peptide that has gone through full US regulatory review, and the compounding landscape for peptide substances like this one has been an area of ongoing FDA scrutiny. Long term safety in healthy, non-patient populations using it for general immune or longevity purposes has not been specifically studied.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.